Aggregated Tau is internalized by microglia and sorted via lysosomal pathways, activating the NLRP3-ASC inflammasome. This process exacerbates both exogenous and endogenous propagation of Tau pathology, offering a new potential therapeutic target for AD. The gene discussed is NLRP3; the disease is Alzheimer disease.